Preeclampsia Detection and Risk Stratification: A New Era in Laboratory Diagnostics
Preeclampsia affects approximately 2–8% of pregnancies globally and is one of the most common complications contributing to maternal and perinatal mortality. Early identification and stratification of women at risk are critical to prevent adverse outcomes, but traditional diagnostic tools, such as blood pressure and proteinuria, lack specificity and predictive power.
In this educational webinar, Dr. Michael O’Bryan, Siemens Healthineers, will review the evolving clinical landscape of preeclampsia, including its pathophysiology, diagnostic challenges, and guidelines. The presentation will focus on the role of angiogenic biomarkers (specifically the sFlt-1/PlGF ratio) as a tool to improve diagnostic confidence, reduce unnecessary hospitalizations, and optimize maternal-fetal outcomes.
Drawing on clinical studies and international experience, the webinar will explore how laboratory assays measuring sFlt-1/PlGF can support personalized care, lab workflow efficiency, and improved patient management.
Following this webinar, you will be able to:
- Describe the clinical and diagnostic challenges associated with identifying and managing preeclampsia.
- Explain the pathophysiological role of angiogenic biomarkers in preeclampsia and their relevance in risk assessment.
- Evaluate the clinical utility of the sFlt-1/PlGF ratio test and its impact on patient management, hospital workflows, and decision-making in maternal care.
- Understand how current international guidelines (e.g., ISSHP, NICE, FIGO) incorporate biomarker testing and evolving standards for diagnosing hypertensive disorders of pregnancy.
Who should attend?
- Obstetricians and maternal-fetal medicine specialists
- Clinical pathologists and laboratory directors
- Clinical chemists and medical technologists
- Women’s health providers
- Hospital administrators and care coordinators
- Researchers and healthcare policymakers
- Medical science liaisons and medical affairs professionals
- Professionals involved in diagnostic test implementation or maternal risk stratification
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Speakers
Dr. Michael O’Bryan is the Global Director of Medical Science Liaisons at Siemens Healthineers, and has over 17 years of experience in healthcare, diagnostics, and medical affairs. His background spans medical practice, regulatory strategy, and product development across Class I and II diagnostic devices. Dr. O’Bryan leads global scientific engagement across multiple disease areas and is known for translating complex clinical evidence into insights that support diagnostic innovation and patient-centered care. Passionate about education and innovation, he focuses on bridging science and strategy to advance the global impact of in vitro diagnostics and continues to drive progress in diagnostic medicine.
Moderator
